JP2021525791A - 新たな心不全治療用医薬の使用 - Google Patents

新たな心不全治療用医薬の使用 Download PDF

Info

Publication number
JP2021525791A
JP2021525791A JP2021507507A JP2021507507A JP2021525791A JP 2021525791 A JP2021525791 A JP 2021525791A JP 2021507507 A JP2021507507 A JP 2021507507A JP 2021507507 A JP2021507507 A JP 2021507507A JP 2021525791 A JP2021525791 A JP 2021525791A
Authority
JP
Japan
Prior art keywords
sacubitril
valsartan
molar ratio
patients
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507507A
Other languages
English (en)
Japanese (ja)
Inventor
ブティリン，ドミトロ
ファーバー，フィリップ
ノエ，アデル
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021525791A publication Critical patent/JP2021525791A/ja
Priority to JP2022090079A priority Critical patent/JP2022116278A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021507507A 2018-08-23 2019-08-22 新たな心不全治療用医薬の使用 Pending JP2021525791A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022090079A JP2022116278A (ja) 2018-08-23 2022-06-02 新たな心不全治療用医薬の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18190588 2018-08-23
EP18190588.6 2018-08-23
EP18199733 2018-10-10
EP18199733.9 2018-10-10
PCT/IB2019/057081 WO2020039386A1 (en) 2018-08-23 2019-08-22 New pharmaceutical use for the treatment of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022090079A Division JP2022116278A (ja) 2018-08-23 2022-06-02 新たな心不全治療用医薬の使用

Publications (1)

Publication Number Publication Date
JP2021525791A true JP2021525791A (ja) 2021-09-27

Family

ID=68069829

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507507A Pending JP2021525791A (ja) 2018-08-23 2019-08-22 新たな心不全治療用医薬の使用
JP2022090079A Pending JP2022116278A (ja) 2018-08-23 2022-06-02 新たな心不全治療用医薬の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022090079A Pending JP2022116278A (ja) 2018-08-23 2022-06-02 新たな心不全治療用医薬の使用

Country Status (6)

Country Link
US (1) US20210177803A1 (cg-RX-API-DMAC10.html)
EP (1) EP3840746A1 (cg-RX-API-DMAC10.html)
JP (2) JP2021525791A (cg-RX-API-DMAC10.html)
KR (1) KR20210032437A (cg-RX-API-DMAC10.html)
CA (1) CA3110152A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020039386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240173982A (ko) 2023-06-07 2024-12-16 인제대학교 산학협력단 세레블론 단백질 또는 상기 단백질을 코딩하는 유전자를 유효성분으로 포함하는 심부전 진단용 바이오마커 조성물 및 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528303A (ja) * 2013-08-26 2016-09-15 ノバルティス アーゲー 新規使用
WO2016181284A1 (en) * 2015-05-11 2016-11-17 Novartis Ag Sacubitril-valsartan dosage regimen for treating heart failure
WO2017134600A1 (en) * 2016-02-03 2017-08-10 Novartis Ag New use of a combination of sacubitril and valsartan

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE60315795T2 (de) 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR101589317B1 (ko) 2007-11-06 2016-01-28 노파르티스 아게 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물
CN103079554A (zh) 2010-08-24 2013-05-01 诺华有限公司 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
CN105102440A (zh) 2012-10-16 2015-11-25 埃克斯福科技公司 单醣至5-(氯甲基)-2-呋喃甲醛的有效、高产率转化
EP3038653A1 (en) 2013-08-26 2016-07-06 Novartis AG New use
CN106414416B (zh) 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105461647B (zh) 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN105503760A (zh) 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
DK3229799T3 (en) 2014-12-08 2019-02-11 Crystal Pharmatech Co Ltd CRYSTALLINIC FORMS OF SUPRAMOLECULATED TRINATRIUM COMPLEX, INCLUDING VALSARTAN AND AHU-377, AND PROCEDURES THEREOF
WO2016051393A2 (en) 2014-12-26 2016-04-07 Crystal Pharmatech Inc. Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
US10562866B2 (en) 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
CN106032361A (zh) 2015-03-11 2016-10-19 齐鲁制药有限公司 Lcz-696的新晶型及其制备方法
WO2016151525A1 (en) 2015-03-26 2016-09-29 Dr. Reddy’S Laboratories Limited Crystalline form of lcz-696
WO2016193883A1 (en) 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
EP3828175A1 (en) 2015-06-12 2021-06-02 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
CN106316973A (zh) 2015-07-07 2017-01-11 江苏柯菲平医药股份有限公司 血管紧张素受体拮抗剂和nep抑制剂药物晶型及其制备
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017009784A1 (en) 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
CN105037289B (zh) 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
EP3117823A1 (en) 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
AU2016314543B2 (en) 2015-08-28 2020-07-16 Hetero Labs Ltd. Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound
WO2017037596A1 (en) 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017036420A1 (zh) 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
WO2017042700A1 (en) 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105669581B (zh) 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN106854187B (zh) 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
CN105929031B (zh) 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN107033094A (zh) 2016-02-04 2017-08-11 南京卡文迪许生物工程技术有限公司 一种药物共晶的晶型及其制备方法和组合物
WO2017154017A1 (en) 2016-03-07 2017-09-14 Msn Laboratories Limited Process for the preparation of trisodium (4-{[1s,3r)-1-([1,1'-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tetrazol-1-id-5-yl)[1,1'-biphenyl]-4-yl]methyl}- l-valinate) and its polymorphs thereof
WO2017191619A2 (en) 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A process for the preparation of a salt of sacubitril and valsartan
TW201806936A (zh) 2016-08-24 2018-03-01 中化合成生技股份有限公司 無定形纈沙坦/沙庫比曲三鈉鹽及其製備方法
EP3522886A4 (en) 2016-10-10 2020-02-19 Laurus Labs Limited STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
WO2018078592A1 (en) 2016-10-28 2018-05-03 Biocon Limited Amorphous trisodium sacubitril valsartan and process for its preparation
CN106518709A (zh) 2016-11-07 2017-03-22 济南益新医药技术有限公司 一种无定形沙库比曲缬沙坦钠盐复合物的制备方法
CN111592500A (zh) 2017-01-03 2020-08-28 上海博志研新药物技术有限公司 ARB-NEPi复合物、晶型、制备方法及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528303A (ja) * 2013-08-26 2016-09-15 ノバルティス アーゲー 新規使用
WO2016181284A1 (en) * 2015-05-11 2016-11-17 Novartis Ag Sacubitril-valsartan dosage regimen for treating heart failure
WO2017134600A1 (en) * 2016-02-03 2017-08-10 Novartis Ag New use of a combination of sacubitril and valsartan

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMERICAN HEART JOURNAL, vol. 198, JPN6021027482, April 2018 (2018-04-01), pages 145 - 151, ISSN: 0004551045 *
CURR HEART FAIL REP, vol. 13, JPN6021027483, 2016, pages 172 - 180, ISSN: 0004820007 *
ESC HEART FAILURE, vol. 5, JPN6021027481, October 2017 (2017-10-01), pages 184 - 188, ISSN: 0004551046 *
ESC HEART FAILURE, vol. 5, JPN6021027485, 14 December 2017 (2017-12-14), pages 327 - 336, ISSN: 0004820005 *
EUROPEAN JOURNAL OF HEART FAILURE, vol. 19, JPN6021027484, 2017, pages 412 - 413, ISSN: 0004820006 *

Also Published As

Publication number Publication date
US20210177803A1 (en) 2021-06-17
KR20210032437A (ko) 2021-03-24
JP2022116278A (ja) 2022-08-09
WO2020039386A1 (en) 2020-02-27
CA3110152A1 (en) 2020-02-27
EP3840746A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
EP3626270B1 (en) Treatment of cardiovascular diseases
EP2887961B1 (en) Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
EP4212152B1 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
US20240216404A1 (en) Methods of treating heart failure with reduced ejection fraction
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
EP3411021B1 (en) New use of a combination of sacubitril and valsartan
US20160206597A1 (en) New Use
CN105324112A (zh) 用于治疗腹泻的产品和方法
JP2022116278A (ja) 新たな心不全治療用医薬の使用
TW202525278A (zh) 治療慢性腎病及高血壓之方法
JP2025536789A (ja) １型糖尿病における慢性腎臓病の治療
RU2860237C2 (ru) Способы лечения подагры
HK1205930B (en) Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210226

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220602

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220610

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220708

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220712